Akeso says China NMPA approves ivonescimab plus chemo for first-line squamous NSCLC

PUBT · 1d ago
Akeso says China NMPA approves ivonescimab plus chemo for first-line squamous NSCLC
  • China’s NMPA cleared ivonescimab with chemotherapy for first-line advanced squamous non-small cell lung cancer.
  • Phase III HARMONi-6 showed longer overall survival than tislelizumab with chemotherapy; median 27.9 months versus 23.7 months.
  • Progression-free survival improved to 11.1 months from 6.9 months; hazard ratio 0.60.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN24853) on August 12, 2026, and is solely responsible for the information contained therein.